News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

EXACT Sciences Corporation (EXAS) Eyes Sale of Another $200 Million in Stock


3/6/2013 9:04:18 AM

Exact Sciences has filed a shelf registration that will let the company sell up to another $200 million worth of stock to the public over the next three years. The Madison company, which is developing a non-invasive, stool-based test for colorectal cancer, has no plans to sell any of the shares in the near future, chief executive Kevin Conroy said.


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES